SCHEMBL6538944

SCHEMBL6538944

CCCCCCO[CH]CCCCCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.54
PPARA Q07869 2/20 0.47
PPARG P37231 1/20 0.46
HTR2A P28223 2/20 0.44
SIGMAR1 Q99720 2/20 0.44
BCHE P06276 1/20 0.43
ALDH1A1 P00352 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ESR1 P03372 2/20 0.42
ADRA2A P08913 2/20 0.42
ADORA3 P0DMS8 2/20 0.42
TACR2 P21452 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
SHBG P04278 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538967 0.98 KCNH2 (0.51) KCNH2PPARAPPARGHTR2ASIGMAR1
SCHEMBL6538484 0.95 KCNH2 (0.51) KCNH2PPARAHTR2ASIGMAR1BCHE
SCHEMBL6756009 0.90 KCNH2 (0.45) KCNH2PPARAHTR2ASIGMAR1TP53
SCHEMBL6539292 0.89 SIGMAR1 (0.46) KCNH2PPARASIGMAR1ALDH1A1
SCHEMBL10736052 0.80 CETP (0.47) KCNH2PPARASLC6A4TP53HTR2C
SCHEMBL2761591 0.80 KCNH2 (0.45) KCNH2ALDH1A1LMNATP53
SCHEMBL2762162 0.80 KCNH2 (0.45) KCNH2ALDH1A1LMNATP53
SCHEMBL8338694 0.80 CETP (0.47) KCNH2PPARASLC6A4TP53HTR2C
SCHEMBL10733438 0.80 CETP (0.47) KCNH2PPARASLC6A4TP53HTR2C
SCHEMBL19322733 0.80 KCNH2 (0.59) KCNH2HTR2ASIGMAR1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743776-B2 ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-01 US disclosed
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY ASTELLAS PHARMA INC. (JP) 2002-12-19 US disclosed
EP-0941236-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-09-15 EP disclosed
WO-1998023637-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY NGLY1, CHIT1, MANBA KCNH2 2461/4885PPARA 4663/4885PPARG 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.